t
| Date | 14 Jul 2022 |
| Time | 07:00:07 |
| Category | Miscellaneous |
| ID | 4273S |
Thursday, 14 July 2022
Dechra® Pharmaceuticals PLC
(Dechra, Company or the Group)
Refinancing of the Group Debt Facilities
Private Placement: Euro Senior Unsecured Notes
Dechra is pleased to announce the signing of a private placement of EUR50 million seven year and EUR 100 million ten year new senior unsecured notes. The issue has similar covenants to the Group's existing facilities. The weighted average coupon of the fixed rate notes will equate to 3.8%.
The issue was priced on 1 July 2022 and the agreement was signed on 14 July 2022. The notes will be issued on 14 July 2022 subject to satisfaction of customary closing conditions.
The private placement is being undertaken now to achieve the Group's aim of ensuring diversified sources of funding and to extend the Group's debt maturity profile. All proceeds from the placement will be used to repay existing debt on the Group's revolving Credit Facility.
|
Enquiries to: |
|
Dechra Pharmaceuticals PLC |
|
Ian Page, Chief Executive Officer |
|
Paul Sandland, Chief Financial Officer |
|
Office: +44 (0) 1606 814 730 |
|
e-mail: [email protected] |
|
|
|
TooleyStreet Communications Ltd |
|
Fiona Tooley, Director |
|
Mobile: +44 (0) 7785 703 523 |
|
e-mail: [email protected] |
|
|
About Dechra
Dechra is a global veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. For more information please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.